Not Yet RecruitingPhase 3ACTRN12609000126213

Pharmacokinetics of 0.25% levobupivacaine with clonidine following caudal epidural administration in children

A non-randomised single group study on the pharmokinetics of 0.25% levobupivacaine with clonidine administered caudally in children undergoing elective sub-umbilical surgical procedures for which caudal epidural analgesia is indicated

Sponsor

Royal Children's Hospital

Enrollment

50 participants

Start Date

Jan 12, 2009

Study Type

Interventional

Conditions

Children undergoing elective sub-umbilical surgical procedures for which caudal epidural analgesia is indicated.

Summary

The aim of this study is to determine how clonidine affects the absorption of levobupivacaine in children having caudal anaesthesia for sub-umbilical surgery. Our study hypothesis is that the absorption of levobupivacaine will be affected when administered in conjunction with clonidine via the caudal route.

Eligibility

Sex: Both males and femalesMin Age: 0 YearssMax Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study measures how the pain-relief drugs levobupivacaine and clonidine are processed in children's bodies when given through a caudal epidural (an injection near the tailbone) during surgery below the belly button. It is for children under 18 undergoing such surgery. Blood samples are taken at set times to understand how the drugs move through the body.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Participants will recieve 0.25% levobupivacaine in a volume to be determined by the attending anaesthetist with clonidine 2mcg/mL, via the caudal route, under general anaesthesia

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12609000126213